Osimertinib is currently the most potent TKI for first-line treatment of patient with metastatic NSCLC harboring common (delEx19, L858R) EGFR mutations in terms of progression-free survival (Soria et al. 2018). Here, EGFR is linked to non-small cell lung carcinoma.